GEP201706651B - Rapamycin composition - Google Patents

Rapamycin composition

Info

Publication number
GEP201706651B
GEP201706651B GEAP201213520A GEAP2012013520A GEP201706651B GE P201706651 B GEP201706651 B GE P201706651B GE AP201213520 A GEAP201213520 A GE AP201213520A GE AP2012013520 A GEAP2012013520 A GE AP2012013520A GE P201706651 B GEP201706651 B GE P201706651B
Authority
GE
Georgia
Prior art keywords
poly
rapamycin composition
ethylene oxide
rapamycin
oxide
Prior art date
Application number
GEAP201213520A
Other languages
English (en)
Inventor
Grzegorz Pietrzynski
Valery Alakhov
Kishore Patel
Original Assignee
Everon Biosciences Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Everon Biosciences Inc filed Critical Everon Biosciences Inc
Publication of GEP201706651B publication Critical patent/GEP201706651B/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/436Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0053Mouth and digestive tract, i.e. intraoral and peroral administration
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/145Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/146Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/06Immunosuppressants, e.g. drugs for graft rejection

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Transplantation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Processes Of Treating Macromolecular Substances (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
GEAP201213520A 2011-12-13 2012-12-13 Rapamycin composition GEP201706651B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US13/324,407 US8912215B2 (en) 2011-12-13 2011-12-13 Rapamycin composition

Publications (1)

Publication Number Publication Date
GEP201706651B true GEP201706651B (en) 2017-04-10

Family

ID=48572556

Family Applications (1)

Application Number Title Priority Date Filing Date
GEAP201213520A GEP201706651B (en) 2011-12-13 2012-12-13 Rapamycin composition

Country Status (8)

Country Link
US (1) US8912215B2 (enExample)
EP (1) EP2790700B1 (enExample)
JP (1) JP6077001B2 (enExample)
CN (1) CN104379215B (enExample)
GE (1) GEP201706651B (enExample)
RU (1) RU2557919C1 (enExample)
UA (1) UA115137C2 (enExample)
WO (1) WO2013090602A2 (enExample)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HUP1400075A2 (hu) 2014-02-14 2015-08-28 Druggability Technologies Ip Holdco Jersey Ltd Sirolimus és származékainak komplexei, elõállítása és gyógyszerészeti kompozíciói
CN105794803B (zh) * 2016-05-06 2018-06-05 重庆大学 Tor蛋白抑制剂抑制植物枯萎病菌、黄萎病菌的新用途
CN105918330B (zh) * 2016-05-24 2018-06-05 重庆大学 雷帕霉素抑制植物早疫病菌的新用途
CN112137961A (zh) * 2020-09-30 2020-12-29 严鹏科 一种雷帕霉素组合物及其制备方法
WO2023145867A1 (ja) * 2022-01-31 2023-08-03 住友精化株式会社 製剤用ポリアルキレンオキシド粒子、医薬用組成物、製剤用組成物及び製剤

Family Cites Families (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL102414A (en) 1991-07-25 1996-08-04 Univ Louisville Res Found Medicinal preparations for the treatment of ocular inflammation, containing rapamycin
US6277410B1 (en) * 1992-10-08 2001-08-21 Supratek Pharma Inc. Copolymer compositions for oral delivery
US5840319A (en) 1992-10-08 1998-11-24 Alakhov; Valery Yu Biological agent compositions
US7205279B2 (en) * 1995-10-25 2007-04-17 Novartis Ag Pharmaceutical compositions
BE1009856A5 (fr) * 1995-07-14 1997-10-07 Sandoz Sa Composition pharmaceutique sous la forme d'une dispersion solide comprenant un macrolide et un vehicule.
US6060518A (en) 1996-08-16 2000-05-09 Supratek Pharma Inc. Polymer compositions for chemotherapy and methods of treatment using the same
CA2230748C (en) * 1997-03-14 2010-08-03 American Home Products Corporation Rapamycin formulations for oral administration
US8257725B2 (en) 1997-09-26 2012-09-04 Abbott Laboratories Delivery of highly lipophilic agents via medical devices
US6248363B1 (en) 1999-11-23 2001-06-19 Lipocine, Inc. Solid carriers for improved delivery of active ingredients in pharmaceutical compositions
US7256180B2 (en) 2000-04-28 2007-08-14 Supratek Pharma Inc. Compositions and methods for inducing activation of dendritic cells
US20030054042A1 (en) * 2001-09-14 2003-03-20 Elaine Liversidge Stabilization of chemical compounds using nanoparticulate formulations
ES2428354T3 (es) 2002-09-18 2013-11-07 Trustees Of The University Of Pennsylvania Rapamicina para usar en la inhibición o prevención de la neovascularización coroidea
US9216106B2 (en) 2003-04-09 2015-12-22 Directcontact Llc Device and method for the delivery of drugs for the treatment of posterior segment disease
US7083802B2 (en) 2003-07-31 2006-08-01 Advanced Ocular Systems Limited Treatment of ocular disease
AU2004274026A1 (en) 2003-09-18 2005-03-31 Macusight, Inc. Transscleral delivery
US20070059336A1 (en) 2004-04-30 2007-03-15 Allergan, Inc. Anti-angiogenic sustained release intraocular implants and related methods
US8663639B2 (en) 2005-02-09 2014-03-04 Santen Pharmaceutical Co., Ltd. Formulations for treating ocular diseases and conditions
CN101137365A (zh) 2005-03-08 2008-03-05 生命周期药物公司 包含西罗莫司和/或其类似物的药物组合物
JP2008533204A (ja) 2005-03-21 2008-08-21 マクサイト, インコーポレイテッド 病気又は症状の治療のためのドラッグ送達システム
US20060247265A1 (en) 2005-04-28 2006-11-02 Clackson Timothy P Therapies for treating disorders of the eye
US20090053391A1 (en) 2005-12-06 2009-02-26 Ludwig Florian N Method Of Coating A Drug-Releasing Layer Onto A Substrate
BRPI0707612B8 (pt) 2006-02-09 2021-05-25 Macusight Inc vaso lacrado e formulações líquidas contidas no mesmo
US8148338B2 (en) * 2006-02-22 2012-04-03 Supratek Pharma Inc. Doxorubicin formulations for anti-cancer use
EP2001466B1 (en) 2006-03-23 2016-01-06 Santen Pharmaceutical Co., Ltd Low-dose rapamycin for the treatment of vascular permeability-related diseases
WO2008022256A2 (en) 2006-08-16 2008-02-21 Blagosklonny Mikhail V Methods and compositions for preventing or treating age-related diseases
GB0625844D0 (en) 2006-12-22 2007-02-07 Daniolabs Ltd The treatment of macular degeneration
US11078262B2 (en) 2007-04-30 2021-08-03 Allergan, Inc. High viscosity macromolecular compositions for treating ocular conditions
WO2009005673A1 (en) 2007-06-28 2009-01-08 Schering Corporation Anti-igf1r
US20090035381A1 (en) 2007-08-01 2009-02-05 Stankus John J Electrospraying method for fabrication of particles and coatings and treatment methods thereof
WO2009023877A2 (en) 2007-08-16 2009-02-19 Macusight, Inc. Formulations for treatment of ocular diseases or conditions
ES2667945T3 (es) 2007-10-08 2018-05-16 Aurinia Pharmaceuticals Inc. Composiciones oftálmicas que comprenden inhibidores de calcineurina o Inhibidores de mTOR
CA2696977C (en) 2007-10-16 2012-12-04 Pharmathen S.A. Improved pharmaceutical composition containing a pyrrolidone anticonvulsant agent and method for the preparation thereof
EP2227085A4 (en) 2007-12-06 2013-10-09 Berg Pharma Llc INGREDIBLE COMPOSITIONS WITH INCREASED BIOLOGICAL AVAILABILITY
US20090291073A1 (en) 2008-05-20 2009-11-26 Ward Keith W Compositions Comprising PKC-theta and Methods for Treating or Controlling Ophthalmic Disorders Using Same
US20100040669A1 (en) 2008-08-12 2010-02-18 Higuchi John W Non-Invasive Ocular Delivery of Rapamycin
EP2427174A4 (en) 2009-05-04 2014-01-15 Santen Pharmaceutical Co Ltd HEMMER OF THE MTOR SIGNAL PATH FOR THE TREATMENT OF EYE TROUBLE
CA2665956A1 (en) 2009-05-07 2010-11-07 Samir Patel Combination treatment for ocular diseases
WO2011135580A2 (en) * 2010-04-28 2011-11-03 Cadila Healthcare Limited Pharmaceutical compositions of sirolimus

Also Published As

Publication number Publication date
WO2013090602A3 (en) 2014-12-24
UA115137C2 (uk) 2017-09-25
JP2015513311A (ja) 2015-05-07
EP2790700B1 (en) 2017-10-25
WO2013090602A2 (en) 2013-06-20
US8912215B2 (en) 2014-12-16
RU2557919C1 (ru) 2015-07-27
EP2790700A4 (en) 2015-10-14
CN104379215A (zh) 2015-02-25
CN104379215B (zh) 2017-08-04
EP2790700A2 (en) 2014-10-22
JP6077001B2 (ja) 2017-02-08
US20130150397A1 (en) 2013-06-13

Similar Documents

Publication Publication Date Title
WO2013012476A3 (en) Branched polyether-polyamide block copolymers and methods of making and using the same
IL268295B (en) Parasitic preparations containing the active ingredient isoxazoline, methods and uses thereof
WO2013119916A3 (en) Compounds for treating spinal muscular atrophy
PH12012501355A1 (en) Certain triazolopyridines and triazolopyrazines, compositions thereof and methods of use therefor
WO2014052836A3 (en) Methods and compositions for treating infection
HK1202313A1 (en) Methods and compositions for the treatment and diagnosis of bladder cancer
MX2014008008A (es) Composiciones solidas que comprenden un inhibidor del virus de la hepatitis c.
EP2578033A4 (en) Hybrid mobile phone geopositioning
WO2012167171A3 (en) Z-selective ring-closing metathesis reactions
EP2389894A3 (en) Hydrogel implants with varying degrees of crosslinking
GEP201706651B (en) Rapamycin composition
EP2558431A4 (en) Narrow psd hydraulic cement-scm blends, and methods for making same
IN2014DN06202A (enExample)
GB2496828B (en) TTI Adaptation in E-DCH
WO2012142292A3 (en) Biofunctionalized polymer microparticles for biotherapeutic delivery and processes for using and making the same
WO2012106702A3 (en) Treatment of leukemia
BR112012000506A2 (pt) composições de copolímero em bloco de óxido de etileno óxido de butileno
SG10201710919QA (en) Bleed resistant, oil-extended olefin block copolymer composition with surface-active agent
WO2013013240A3 (en) Macrocyclic compounds and related compositons and methods of use
苏柚 Special Talk Of AN JELL
肖昕 Luxgen7 SUV
周静 Purple Onion
朱慧 Twenty-One Forever
罗晓立 The Wizarding World of Harry Potter
王俐 Forgiveness